MedPath
HSA Approval

FESPIXON CREAM

SIN16683P

FESPIXON CREAM

FESPIXON CREAM

January 31, 2023

PHARMENG TECHNOLOGY PTE. LTD.

PHARMENG TECHNOLOGY PTE. LTD.

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantPHARMENG TECHNOLOGY PTE. LTD.
Licence HolderPHARMENG TECHNOLOGY PTE. LTD.

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

CREAM

**3\. Dosage and Administration** FESPIXON is prescription-only. FESPIXON shall be topically applied to the lesion twice daily by fully covering the ulcer. Once FESPIXON is applied, gauze should be used to cover the ulcer area. The lesion shall avoid being overwrapped until healing of ulcer has occurred.

TOPICAL

Medical Information

**2\. Indication** **Diabetic foot ulcer** Note: The clinical trial results are based on the subjects with non-ischaemic Wagner Grade 1 and Grade 2 chronic diabetic ulcers without active infection.

**4\. Contraindications** FESPIXON is contraindicated in the patients who are hypersensitive to the ingredients of FESPIXON, including _Plectranthus amboinicus_, _Centella asiatica_ or excipients.

Pending

xpending

Manufacturer Information

PHARMENG TECHNOLOGY PTE. LTD.

Oneness Biotech Co., Ltd., Nanchou Plant

Active Ingredients

Plectranthus amboinicus extract (PA-F4)

2.5mg/g

plectranthus amboinicus extract (pa-f 4)

Centella asiatica extract (S1)

10mg/g

Centella asiatica

Documents

Package Inserts

Fespixon PI approved 2023.pdf

Approved: January 31, 2023

Download

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.